Cathepsin B

Cathepsin B (CTSB) is a lysosomal cysteine protease predominantly localized in endosomal and lysosomal compartments, where it participates in intracellular and extracellular protein turnover and contributes to cellular proteolysis pathways[1][2]. Cathepsin B is among the most abundant lysosomal proteases and functions in protein degradation, lysosomal homeostasis, and cellular turnover, linking its activity to fundamental endo/lysosomal biological processes[1][2]. Mechanistically, Cathepsin B regulates multiple forms of programmed cell death, including apoptosis, pyroptosis, ferroptosis, necroptosis, and autophagic cell death, thereby connecting lysosomal proteolysis with cell fate determination pathways[2]. In disease models, dysregulated Cathepsin B activity contributes to neurological disorders, cardiovascular disease, inflammatory conditions, and multiple cancers, where elevated expression is frequently associated with pathological progression, tissue remodeling, invasion, and metastasis[2][3]. Compared with related cysteine cathepsins such as Cathepsin L, which is strongly involved in antigen processing, proprotein processing, and degradation of extracellular matrix proteins including collagen and elastin, Cathepsin B is distinguished by its characteristic endopeptidase and exopeptidase activities and its prominent role in programmed cell death signaling and disease-associated proteolytic networks[4][2]. For experimental applications, Cathepsin B is a widely used pharmacological target, and selective inhibitors including CA-074 and other Cathepsin B inhibitors have been extensively employed to investigate protease-dependent mechanisms and evaluate therapeutic strategies in cancer and other disease models[3][2].